| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 19.519 | 17.204 | 23.470 | 30.131 | 37.497 | 30.617 | 30.419 | 37.131 | 4 | 0 |
| Total Income - EUR | 19.543 | 17.239 | 23.470 | 30.131 | 37.497 | 30.617 | 30.419 | 37.137 | 4 | 0 |
| Total Expenses - EUR | 15.879 | 15.347 | 21.279 | 25.628 | 25.172 | 22.309 | 25.546 | 35.014 | 8.765 | 569 |
| Gross Profit/Loss - EUR | 3.664 | 1.892 | 2.191 | 4.503 | 12.325 | 8.308 | 4.873 | 2.123 | -8.761 | -569 |
| Net Profit/Loss - EUR | 3.078 | 1.560 | 1.954 | 4.201 | 11.950 | 8.097 | 4.721 | 1.608 | -8.761 | -569 |
| Employees | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 |
Check the financial reports for the company - Biosantest Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 21.106 | 22.415 | 24.064 | 23.196 | 22.329 | 23.595 | 26.925 | 29.226 | 23.144 | 23.015 |
| Current Assets | 3.633 | 5.423 | 5.022 | 9.070 | 21.113 | 27.856 | 29.441 | 15.632 | 11.339 | 10.711 |
| Inventories | 2.072 | 2.691 | 1.183 | 1.572 | 3.538 | 5.510 | 5.908 | 1.710 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 206 | 202 | 0 | 0 | 0 |
| Cash | 1.560 | 2.732 | 3.838 | 7.497 | 17.575 | 22.140 | 23.331 | 13.922 | 11.339 | 10.711 |
| Shareholders Funds | 23.370 | 24.692 | 26.229 | 29.949 | 41.319 | 48.632 | 52.275 | 43.373 | 34.480 | 33.718 |
| Social Capital | 52 | 51 | 50 | 49 | 48 | 48 | 46 | 47 | 46 | 46 |
| Debts | 1.368 | 3.147 | 2.857 | 2.317 | 2.123 | 2.819 | 4.091 | 1.485 | 3 | 8 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8690 - 8690" | |||||||||
| CAEN Financial Year |
8690
|
|||||||||
Comments - Biosantest Srl